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that has been implemented in Turkey since December 2012. Total volume of PHI in 
Turkey is expected to expand more as the scope of the supplementary health insur-
ance implementation increases. There exists a diminishing trend of OOP expenses 
across all three countries however this is again relatively much lower for Turkey. 
Since 2003, Turkey has been implementing a Health Transformation Program where 
PHI is expected to play a crucial role to reduce OOP health expenditure. Despite this 
ten-year program, OOP spending has decreased slightly (11%) when compared to 
South Africa where there is a threefold decrease. ConClusions: Turkey has still 
room to improve its private insurance system along with its public system to reduce 
OOP payments. South Africa with private dominant health insurance system and 
lower OOP spending is trying to transfer its resources towards a national health 
insurance system. United States stands as a stabilized private dominant health 
insurance model which significantly differs from Turkey and South Africa.
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THe Role of Big DaTa in HealTH CaRe DeCision Making: an iTalian 
exPeRienCe
De Rosa M., Rossi E., Cataudella S.
CINECA Interuniversity Consortium, Casalecchio di Reno, Italy
objeCtives: The need to use real-world data to support Health Care decision was 
the main driver for the Italian Inter-University Consortium (CINECA) to set-up a 
population-based patient centric database (ARNO Observatory) which integrates 
big administrative data from National/ Regional Information Systems to monitor 
health economics, patient’s outcomes and measure health performance in the 
real world. Methods: On a population of almost 12 million, since 1987, ARNO 
Observatory routinely collects and integrates NHS administrative data for each 
single patient with high quality and complete information. ARNO provides com-
prehensive data referred to patient as: demographics, outpatient drug prescrip-
tions, inpatient hospital discharges, imaging and lab tests prescriptions. From 
ARNO Observatory we carried out analyses of population or on specific cohorts 
to evaluate prevalence of chronic disease, co-morbidities and cost of total burden 
of illness. Results: From a cohort of 2,5 million of ARNO population, one third 
subjects has at least one chronic disease during 2012 and this proportion rises with 
ages (84% in elderly over 80 years). The most common chronic disease is hyper-
tension (23%), followed by COPD/asthma (13%), dyslipidemia (10%) and diabetes 
(6,3%). Integration of different data flows led to the evaluation of cost of illness 
which varies from 2.000€ for hypertension or 2.800€ for diabetes to 12.000€ for Acute 
Coronary Syndrome. Most part of this cost is due to hospitalization (49% vs 40% for 
drugs and 12% for diagnostic examination and lab tests). Cost of illness is strictly 
correlated to age and presence of co-morbidities, actually a considerable number 
of patients has more than one disease (17%), in elderly this percentage rises up 
to 50%. ConClusions: A big data infrastructure is very important to integrate 
administrative and clinical data for real world analyses and it is a valid instrument 
to support clinical governance and clinical research decision making.
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objeCtives: Estimate the financial savings associated with participation in a 
transitional case management (TCM) program offered by Optum. Nurses managed 
cases via telephone and face-to-face interventions following member’s inpatient 
admission. The program was designed to improve care and help save money by 
better managing post-discharge care of the participants. Methods: Propensity-
score-weighted difference-in-difference multiple regression analyses were used to 
estimate savings in total health care expenditures associated with active engage-
ment in the CAD program. Factors associated with the program participation and 
savings were also found via logistic regression. The study included cohorts of 80,032 
participants and 29,054 non-participants who qualified for the program between 
July 2011 and December 2012. Pre- and post-program engagement periods extended 
for up to 12 months before and after the dates members qualified for the program. 
Regression models controlled for age, gender, and health conditions along with 
inferred demographic characteristics such as minority status, education, income, 
and the supply of health care services in members’ zip code of residence. Results: 
The regression-adjusted average cost trend was $231 lower per member per month 
for program participants. About 42.4% of the participants were managed in a way 
that their cost savings exceeded the costs of providing the program. Factors asso-
ciated with engagement were not always associated with program savings. For 
example, lower income and lower supply of health care service areas were associ-
ated with lower participation rates but higher saving. On the other hand, those with 
higher risk scores and in higher age group were more likely to engage and also more 
likely to be managed in a way that lead to savings as well. ConClusions: The TCM 
program helped to generate savings. Analyses of participation and savings allowed 
program providers to understand the pockets of program success and streamline 
future efforts to improve the program.
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objeCtives: Taiwan’s National Health Insurance, established in 1995, has offered 
every citizen nearly equal financial access to comprehensive health services and 
provides all citizens with financial risk protection from large medical expenses. 
Existing data reported that purchasing private life and annuity insurances is popular 
in Taiwan, with an average of 2.3 contracts per person and 18% of GDP invested in 
products. The average prices per physical unit and price changes after the policy 
varied significantly by manufacturer type: 1.8 EGP (0.26 $USD) for drugs produced by 
state-owned companies increased by 238%, 2.3 EGP for domestic-private company 
products increased by 10%, 13 EGP for multinationals products decreased by 6%, 
and 41 EGP for imported products increased by 13%. ConClusions: Switching 
to a referent price policy for pharmaceuticals resulted in considerable percentage 
increase, on average, for products where a price change occurred. However, the 
nominal effect was attenuated because the biggest proportional changes occurred 
on the lowest cost drugs.
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fRoM 2010 To 2011 in CHina
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objeCtives: To understand hospitalization costs, costs covered by insurance and 
disease distribution among urban inpatients with basic health insurance (BHI) 
in China between 2010 and 2011, providing data evidence for the government 
to improve BHI policies and drug regulation system in the further. Methods: A 
nationwide, cross-sectional sampling of urban inpatients with BHI was conducted 
in mainland China. A retrospective analysis was adopted and all results were 
extrapolated to the whole country according to the population, economics and 
other factors in the inpatients’ cities. The statistics analysis software was SQL Server 
2003. Results: There were 38.2 million hospitalization cases after extrapolating 
(sample= 375822) in 2011, with an increase of 21.42% than that of the previous year. 
Three-class hospitals received more hospitalization cases (43.56% of the total) in 
2011 than the previous year (40.10% of the total). Average hospitalization cost per 
visit in 2011 was 8210 RMB, an increase of 1.90% from the previous year. Remarkably, 
medication expenses accounted for about 49%, which was approximately equal to 
the previous year. The expenses covered by BHI accounted for 68.39% for each visit, 
which was higher than that of the previous year. Cerebrovascular disease had the 
most hospitalization cases (9.11% of the total), followed by cancer, ischemic heart 
disease, Hypertension and diabetes. The total hospitalization cost of cancer (37.8 bil-
lion RMB) was the highest, followed by cerebrovascular disease (32.8 billion RMB) and 
ischemic heart disease (25.7 billion RMB). ConClusions: The average hospitaliza-
tion costs per visit and total hospitalization costs all increased. And rational drug 
use should be still paid more attention since the drug costs percentage was steadily 
high. Helping inpatients select proper hospitals to see doctors and strengthening the 
administration of diseases cost highly will be helpful for reducing the medical costs.
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ReTuRn on invesTMenT foR sMall To MiD-size ManufaCTuReRs?
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objeCtives: Analysis of large datasets such as claims and health care utilization 
databases has become a routine way that drug, device and diagnostic manufacturers 
understand current treatment pathways and project market potential for develop-
ment products. The time, resources, and costs associated with these data analyses 
can be a barrier for small- to mid-size companies operating under the pressure of 
lean development processes. We sought to analyze the current published litera-
ture on claims analyses in four therapeutic areas (cardiovascular, ophthalmology, 
oncology, and women’s health) to better understand the size of companies engag-
ing in this type of research. Methods: A literature review of published articles 
from January 1, 2000 – December 31, 2013 was conducted to better understand the 
analyses of large datasets being conducted by company size. The data were then 
abstracted to obtain the following data: therapeutic area, funding support for data 
analysis, company size, large dataset utilized, approximate cost of obtaining data, 
approximate cost of analyzing data, approximate US patient population for drug/
device/diagnostic under development. Results: Analyses of large datasets were 
just as likely to be conducted by government and academic institutions as private 
sector organizations (research firms and manufacturers). Of the 35 articles that 
met inclusion criteria in cardiovascular disease, 19 conducted by private sector 
organizations. For the 19 analyses conducted by private sector organizations, 3 
were conducted by manufacturers, of which two were large pharmaceutical compa-
nies and 1 was a nationwide pharmacy chain. ConClusions: None of the claims 
data conducted by manufacturers were small- to mid-size companies. It is unclear 
whether this is due to the cost of data and analysis or the desire to have a seem-
ingly unbiased third-party author. Further research is needed to determine why 
small- to mid-size drug, device or diagnostic manufacturers are not engaging in 
this type of research.
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uniTeD sTaTes, souTH afRiCa anD TuRkey
Seyhun O., Can H., Erdol S.
Istanbul, Turkey
objeCtives: This poster presents a comparative analysis of the private health care 
insurance systems (PHI) in Turkey, United States and South Africa. Methods: OECD 
publications, Turkish Private Health Insurance Association, World Bank Reports, 
Publications of Turkish Social Security Institution (SSI) and official web pages of US 
and South Africa Departments of Health are examined for 2001-2011. Results: In 
comparison to Turkey; United States and South Africa have similar characteristics 
in terms of PHI dependence prevailing with a higher coverage. Due to lower PHI level 
in Turkey, Out of Pocket (OOP) payments constitute a significantly higher amount. 
In Turkey, PHI coverage has almost tripled over the last 10 years, but still accounts 
only for 3.40 % of the total population. The trend towards strengthening the PHI is 
basically due to the promotion of PHI solutions such as supplementary coverage 
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Regulatory and HTA documents were analyzed to identify the processes of appraisal, 
indications assessed and key factors driving agency decisions. Results: Overall, 
twenty-one indications were appraised for the four biosimilars collectively; 90% of 
appraisals produced a decision of ‘recommended’, 9% were ‘recommended with 
restrictions’, and 1% were ‘not recommended’. Demonstration of clinical compa-
rability between the biosimilar and the reference product was a requirement in 
all countries. Cost-minimization and budget impact analyses were key economic 
decision factors. Some agencies accepted the notion of comparability for extrapola-
tion to indications other than those that had been studied in clinical trials. Pricing 
dynamics were seen to differ between biosimilars, driven by a combination of pric-
ing strategies for reference biologics, and payer and physician reservations about 
potential risks. ConClusions: Regulatory bodies follow common principles of 
assessment but differences exist with respect to scope and choice of reference prod-
uct. Important factors common to reimbursement agencies included comparable 
efficacy and safety of biosimilars to the reference products, and economic consid-
erations; however, they differed in their appraisal processes. The relative weight of 
price versus potential risk may vary with the disease area targeted by the biologic. 
The currently approved biosimilars have been relatively simple biologics to re-create 
and therefore evaluate, but the experience gained should be built upon to address 
the challenges of assessing the increasingly complex biosimilars being developed.
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Karaca Z., Wong H.
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objeCtives: This paper empirically investigates the role of patient-physician 
communication on the likelihood of receiving appropriate care, and its effect on 
health care costs at hospital inpatient settings. Methods: The Healthcare Cost and 
Utilization Project (HCUP) 2008-2010 State Inpatient Databases (SID) for Florida were 
used in this analysis. Then, we linked Florida SID with Florida Physician Licensure, 
the American Hospital Association Annual Survey Database; and the Area Resource 
File. Our key covariate of interest is the association between Spanish speaking phy-
sicians and Hispanic patients with the total costs associated with that visit. We 
started with descriptive analysis. Next, we used logistic regression models to assess 
likelihood of choosing a Spanish speaking physician over other physicians. Next, 
we used generalized linear regression models to estimate and then compare the 
health care costs associated Hispanic patients with Spanish speaking physicians 
against others. We also used Oaxaca-Blinder (OB) Decomposition to compare the 
health care costs between and within Hispanic and non-Hispanic white patients 
across Spanish and non-Spanish speaking physicians. To assess the robustness of 
our baseline results, we conducted several empirical estimations and tested their 
significance. Results: Our risk adjusted estimates show that the odds ratios for 
Hispanic patients registered to Spanish speaking physicians is 3.8 compared to 
non-Hispanic white patients registered to Spanish speaking physicians. We found 
that hospital inpatient costs associated with Hispanic patients registered to Spanish 
speaking physicians is about $650 less relative to Hispanic patients registered to 
non-Spanish speaking physicians. Our risk-adjusted results also show that hospi-
tal inpatient costs associated with non-Hispanic white patients registered to non-
Spanish speaking physicians relative to the non-Hispanic white patients registered 
to Spanish speaking physicians are lower by about $700 per visit. ConClusions: 
We found a strong correlation between Hispanic patients and Spanish speaking 
physicians. Better communications between patients and providers can provide 
patients with better care.
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objeCtives: The primary objective of this study is to examine the hospitals’ risk-
adjusted costs, and Medicare Advantage (MA) enrollees and Fee-for-service (FFS) 
beneficiaries’ use of high-cost hospitals. The second objective of this study is to 
document the variation in racial and ethnic disparity in visiting high-cost hospitals 
within and between MA enrollees and FFS beneficiaries as policymakers mostly have 
focused on the location of care as an explanation for important disparities in many 
health outcomes. Methods: We used 2006-2010 Healthcare Cost and Utilization 
Project State Inpatient Databases from California, Florida, Massachusetts, New York, 
Tennessee and Wisconsin; American Hospital Association Annual Survey Database; 
and Area Resource Files. We calculated the hospital cost index by dividing the actual 
total costs by casemix adjusted total costs. Next, we calculated three categorical 
values to define the dependent variable for each state, which takes value 1 if the 
hospital cost-index is less than 0.95; value 2 if it is within 0.95 -1.05; and, value 3 if it 
is greater than 1.05. We used ordered logistic regression models. We also estimated 
the same model using a different specification of high-cost hospital definitions to 
ascertain any effects resulting from sample sizes. Results: We found lower preva-
lence of high-cost hospitals among MA enrollees than among FFS beneficiaries. Our 
risk adjusted results show that the odds ratios of visiting a high-cost hospital for MA 
enrollees range from 0.641 to 0.958 for all states. Our results show that non-white 
elderly patients associated with lower likelihood of visiting high-cost hospitals in 
in California and New York, and higher likelihood of visiting high-cost hospitals in 
Florida, Massachusetts, Tennessee and Wisconsin. ConClusions: MA enrollees 
mostly utilize low-cost hospitals for their health care needs. We find sizable geo-
graphic variation in visiting high-cost hospitals among minority elderly population.
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life insurances, ranking #1 worldwide in 2012. For individuals who purchase private 
insurances to add protections it is natural to ask which insurance policy provides the 
most favorable return. The objective of this study is to establish a valuation system 
for private life and annuity insurance plans using a robust, flexible, distributed 
cloud computing architecture. Methods: Using the fixed income model and by 
constructing polynomial interpolated yield curves from Taiwan government and 
corporate bonds, we can approximate the internal rate of returns of each insur-
ance policy and compare their performance versus the time value of money of 
the total investments. We extracted daily information from over-the-counter mar-
kets and Taiwan interbank interest rates to compute daily changes in policy val-
ues. Results: Shown in our experiments, by investing in insurance policies from 
30 to 85 years old, the policies provide -0.1% to -1.4% returns, which represents the 
total value of investments has diminished throughout the years. Even in the event 
of benefit claims (severe injury or death), the insurances provides -0.2% to 1.5% 
returns. For annuity insurances, early investments do not provide advantages, i.e., 
by investing at 30 and by 50 years old, the returns is approximately the same at 85 
years old. ConClusions: We establish a robust, flexible and efficient valuation 
system for private life and annuity insurance plans. Results show that even by 
purchasing private insurances, the extra protections provided is still inadequate to 
cover major emergency medical conditions.
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objeCtives: The objective of this study is to estimate the effects of the 
Massachusetts health care reform on the use of inpatient hospital services in 
Massachusetts. Methods: We used Healthcare Cost and Utilization Project State 
Inpatient Databases for the years 2004-2011 in 37 states including Massachusetts. 
We identified a control group of hospitals from other states for each year based on 
their characteristics that match the hospitals in Massachusetts. Hospital-specific 
utilization was summarized by calendar quarter, and difference-in-differences time 
series models were estimated based on the multi-year implementation of reform 
initiatives in Massachusetts. We identified a pre-reform period (Q1 2004-Q3 2006), 
during period (Q4 2006-Q2 2007), and two post-reform periods (Q3 2007-Q1 2009 and 
Q2 2009-Q4 2011). Dependent variables were the quarterly estimate for each hospital 
of the natural logarithm of total discharges, average length of stay, the coefficient of 
variation in length of stay, and cost per discharge. Independent variables included 
annual measures of the Herfindahl-Hirschman Index, county-level measures of popu-
lation, household income, unemployment rate, labor force participation rate and a 
dichotomous variable indicating if the hospital was in Massachusetts and the stage of 
policy implementation in the state. The regression models also controlled for the dif-
ferential effects of the dramatic changes that occurred across the country. Results: 
Our descriptive results indicate that the number of discharges grew more rapidly in 
Massachusetts than in the rest of the country. Our risk adjusted results show that 
the full implementation of the reform legislation led to 5.8% more discharges, 5.0% 
shorter lengths of stay, a 2.5% reduction in the variation in a hospital’s length of stay 
and no change in cost per discharge – all relative to control hospitals. ConClusions: 
Massachusetts health care reform had a modest impact on inpatient utilization and 
that impact became greater the longer the reform was in place.
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objeCtives: Cost effectiveness analyses are required by various Health Technology 
Assessment (HTA) agencies as part of the reimbursement submission. To gain an 
insight into the methods used, we analyzed the cost effectiveness studies for the 
top twenty highest selling drugs (~$90-100B worldwide sales). Methods: The Top 20 
drugs were selected based on their worldwide sales. For this analysis, we segmented 
these drugs into categories such as primary care, specialty, small molecules, bio-
logics, therapy areas, and availability of generic alternatives. We analyzed the cost 
effectiveness studies that were published in peer-reviewed journals. Searches were 
conducted using generic names of the drugs and the phrase “cost effectiveness” in 
an abstract of the published study. Results: Between 2008-2013, the number of 
published studies on “cost effectiveness” has increased by more than 35%. There 
is a large variability in CERs for same drugs for different indications, in some cases 
also varying by biomarkers. Primary care drugs had lower and less variable CERs 
than specialty drugs. Variations also exist in methodology used by different groups 
in modeling cost effectiveness, especially for time horizon and comparator. The 
majority of primary care drugs were modeled for a time horizon of 35-40 years or for 
a lifetime to demonstrate cost effectiveness. ConClusions: This analysis shows 
the range, variability, and methods used for calculation of ICER values for these 
high budget impact drugs and provides lessons for executives and policy makers.
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How aRe BiosiMilaR MeDiCines aPPRaiseD as HealTH TeCHnologies? an 
evaluaTion of aPPRaisal PRoCesses in MulTiPle CounTRies
Smith TA, de Silva SU, Bending MW
Mapi, London, UK
objeCtives: Biosimilars are biotherapeutic products that are similar in terms of 
quality, safety and efficacy to an already licensed reference biologic. There are strict 
guidelines in place for the regulatory approval of biosimilars. However, HTA agen-
cies differ in their approaches to appraisal of biosimilars. This study examined 
the factors influencing regulatory and reimbursement decisions for biosimilars in 
different countries. Methods: A qualitative documentary analysis was performed 
of the regulatory approval and reimbursement of four biosimilars in nine countries. 
